4.4 Article

Dupilumab-Associated Ocular Surface Disease: Clinical Characteristics, Treatment, and Follow-Up

Journal

CORNEA
Volume 40, Issue 5, Pages 584-589

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/ICO.0000000000002461

Keywords

dupilumab; conjunctivitis; dupilumab-associated ocular surface disease; DAOSD

Categories

Funding

  1. National Institutes of Health (Bethesda, MD) [P30 EY010572]
  2. Research to Prevent Blindness (New York, NY)

Ask authors/readers for more resources

This study evaluated a consecutive case series of patients with Dupilumab-associated ocular surface disease (DAOSD), describing common ocular symptoms and signs, proposing a symptom-based grading system, and highlighting the efficacy of treatments like topical corticosteroids. By utilizing a symptom-based grading scale, the study provides insights for nonophthalmic physicians to guide ophthalmology consultations.
Purpose: A consecutive case series of patients with dupilumab-associated ocular surface disease (DAOSD) that describes common ocular symptoms and signs, proposes a symptom disease severity grading system, and describes treatment strategies of DAOSD patients was evaluated. Methods: A retrospective chart review of patients with concomitant dupilumab-treated atopic dermatitis and DAOSD with ophthalmic evaluation between January 2014 and May 2019 was conducted. Results: Twenty-nine patients (mean age 46 years, M/F: 12/17) with 57 ophthalmic exams were identified. The most common ocular symptoms included irritation/pain (n = 28, 97%), redness (n = 24, 83%), pruritus (n = 18, 62%), discharge (n = 18, 62%), and light sensitivity (n = 6, 21%). The most frequent signs included conjunctival injection (n = 18, 62%), superficial punctate keratitis (n = 16, 55%), and papillary reaction (n = 8, 28%). Topical corticosteroids (TCS) (n = 23, 79%), tacrolimus (n = 6, 21%), and artificial tears (n = 7, 24%) were the most commonly used therapies. Of those with follow-up documentation (n = 21), 20 were noted to have partial or complete response with TCS based on symptoms and reduction of signs. Using our proposed symptom-based grading scale, scaled 1 to 5 based on the presence of common symptoms listed above, 66% (n = 19) requiring topical immunomodulating therapy were found in the 'severe' group (>= 3 symptoms) and 17% (n = 5) were found in the 'mild' group (<= 2 symptoms). Conclusions: This study provides insight into the commonly presenting ocular signs and symptoms associated with DAOSD and highlights the efficacy of TCS and other immunomodulators in improving symptoms associated with DAOSD. Based on our findings, we propose a symptom-based grading system that can guide nonophthalmic physicians regarding ophthalmology consult.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available